Abstracts tagged "quality of life"

Abstract Number: 2313 • 2015 ACR/ARHP Annual Meeting
Responder Rates and Numbers Needed to Treat Based on Clinically Meaningful Improvements in Patient Reported Outcomes (PROs) Including Health-Related Quality of Life (HRQoL) after Sarilumab Treatment during a Phase III Randomized Controlled Trial (RCT)
Vibeke Strand¹, Regina Rendas-Baum², George J. Joseph³, Chieh-I Chen⁴, Hubert van Hoogstraten⁵, T. W. J. Huizinga⁶ and Mark C. Genovese⁷, ¹Biopharmaceutical Consultant, Portola Valley, CA, ²QualityMetric Inc, Lincoln, RI, ³Global Health Economics & Outcomes Research (HEOR), Sanofi, Bridgewater, NJ, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Sanofi, Bridgewater, NJ, ⁶Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁷Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Sarilumab is a human monoclonal antibody (mAb) directed against the soluble IL-6 receptor (sIL-6R), administered subcutaneously (SC) every 2 weeks (q2w). In the phase…
Abstract Number: 2330 • 2015 ACR/ARHP Annual Meeting
The Turkish Validity and Reliability of the Systemic Lupus Erythematosus Quality of Life Questionnaire (L-QoL)
M Tuncay Duruoz¹, Canan Sanal Top², Ilhan Sezer³, Figen Yılmaz⁴, Cagri Ünal², Hatica Sule Baklacioglu⁵, Firat Ulutatar⁶ and Pamir Atagunduz⁷, ¹Dept of PM&R, Rheumatology Clinic, Marmara University Medical School, Istanbul, Turkey, ²PM&R, Marmara University Medical School, Istanbul, Turkey, ³Rheumatology, Physical Medicine and Rheabilitation, Antalya Education and Research Hospital, Antalya, Turkey, ⁴PM&R, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey, ⁵Rheumatology, Marmara University Medical School, Istanbul, Turkey, ⁶Physical Medicine and Rehabilitation Department, Marmara University Medical School, Istanbul, Turkey, ⁷Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey
Background/Purpose: The Systemic Lupus Erythematosus Quality of Life Questionnaire (L-QoL) is a disease-specific measure of needs-based quality of life developed in the United Kingdom (1).…
Abstract Number: 2639 • 2015 ACR/ARHP Annual Meeting
Towards Patient-Centeredness of the Treat-to-Target Paradigm: Development of a Framework for Evaluation of Patients with Rheumatoid Arthritis in the Setting of Patient-Physician Discordance
John M. Davis III¹, Tim Bongartz², Zoran Kvrgic², Melissa M. Plagge¹, Cynthia S. Crowson³, Eric L. Matteson⁴, Thomas G. Mason II², Scott T. Persellin⁵, Clement J. Michet Jr.², Theresa Wampler Muskardin¹ and Kerry Wright², ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Division of Rheumatology and Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Division of Rheumatology, Department of Internal Medicine and Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁵Department of Rheumatology, Mayo Clinic Rochester, Rochester, MN
Background/Purpose: A great challenge in managing rheumatoid arthritis (RA) is the scenario of patient-physician discordance, in which despite seeming control of inflammation, patients suffer from…
Abstract Number: 2975 • 2014 ACR/ARHP Annual Meeting
Residual Large Joint Synovitis By Power Doppler Ultrasonography Is Associated with Higher Disease Activity and Significant Impact of Disease in Multi-Ethnic Asian Patients with Established Rheumatoid Arthritis
Yu Xiao Guo¹, Manjari Lahiri^2,3 and Peter Cheung^2,3, ¹Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ²Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ³Division of Rheumatology, National University Hospital, Singapore, Singapore
Background/Purpose Regular monitoring of disease activity with appropriate modification of disease-modifying anti-rheumatic drug (DMARD) therapy results in improved radiographic and functional outcomes in patients with…
Abstract Number: 2721 • 2014 ACR/ARHP Annual Meeting
Patients’ Perspective of Skin Involvement in Systemic Sclerosis
Ada Man¹, Amy Wu¹, Jessica Ziemek², Romy Christmann¹, Robert W. Simms¹, David T. Felson³ and Robert Lafyatis⁴, ¹Rheumatology, Boston University School of Medicine, Boston, MA, ²Rheumatology/Arthritis Center, Boston University School of Medicine, Boston, MA, ³Boston University School of Medicine, Boston, MA, ⁴Arthritis Center, Boston University, Boston, MA
Background/Purpose: Skin tightness and other abnormalities of the skin are the hallmark features of systemic sclerosis (SSc). While skin involvement may significantly impact a…
Abstract Number: 1152 • 2014 ACR/ARHP Annual Meeting
Euroqol-5-Dimensions Utility Gain in Rheumatoid Arthritis, Treated with Abatacept, Rituximab, Tocilizumab or Tumor Necrosis Factor Inhibitors
Anders Gülfe¹, Johan A. Karlsson² and Lars-Erik Kristensen³, ¹Dept of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Faculty of Medicine, Lund, Sweden, ²Dept of Clinical Sciences, Section for Rheumatology, Lund University, Faculty of Medicine, Lund, Sweden, ³Dept of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Faculty of Medicine, Malmö, Sweden
Background/Purpose: We have earlier demonstrated that EuroQoL-5-Dimensions (EQ-5D) utility improves rapidly after commencement of tumor necrosis factor inhibition (TNFi) in rheumatoid arthritis (RA) and other…
Abstract Number: 1150 • 2014 ACR/ARHP Annual Meeting
Marked Differences in Euro-Qol-5-Dimensions Preference Sets Based on Hypothetical or Experience Based Valuation
Anna Cooper¹, Johan A. Karlsson² and Anders Gülfe¹, ¹Dept of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Faculty of Medicine, Lund, Sweden, ²Dept of Clinical Sciences, Section for Rheumatology, Lund University, Faculty of Medicine, Lund, Sweden
Background/Purpose: Health related quality of life (HRQoL) can be expressed as utility, a value anchored at 0 (death) and 1 (perfect health, forming the basis…
Abstract Number: 1078 • 2014 ACR/ARHP Annual Meeting
Work-Related Behavior and Experiences in Patients with Systemic Lupus Erythematosus
Jutta G. Richter¹, Ralph Brinks², Thomas Muth³, Tobias Koch¹, Peter Angerer³ and Matthias Schneider⁴, ¹Department of Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ²Department of Rheumatology, Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany, ³Institute for Occupational and Social Medicine, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ⁴Department of Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany
Background/Purpose: Work-related behavior and experiences are discussed to be either risk factors or resources for individual‘s health. Diseases and related changing working conditions and/or experiences…
Abstract Number: 1077 • 2014 ACR/ARHP Annual Meeting
A Real-World Characterization of US Patients with “Moderate-to-Severe” Systemic Lupus Erythematosus
Vibeke Strand¹, Jennifer Johnson², Carl Vandeloo³, Catrinel Galateanu³ and Steve Lobosco², ¹Biopharmaceutical Consultant, Portola Valley, CA, ²Adelphi Real World Ltd., Macclesfield, United Kingdom, ³UCB Pharma, Brussels, Belgium
Background/Purpose Systemic lupus erythematosus (SLE) is a chronic, inflammatory disease which can impact on patients' Health-Related Quality of Life (HRQoL). This analysis was designed to…
Abstract Number: 1057 • 2014 ACR/ARHP Annual Meeting
Work-Related Behavior and Experiences in Patients with Rheumatoid Arthritis
Jutta G. Richter¹, Thomas Muth², Ralph Brinks³, Tobias Koch¹, Peter Angerer² and Matthias Schneider⁴, ¹Department of Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ²Institute for Occupational and Social Medicine, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ³Department of Rheumatology, Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany, ⁴Department of Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany
Background/Purpose: Work-related behavior and experiences are discussed to be either risk factors or resources for individual‘s health. Diseases and related changing working conditions and/or experiences…
Abstract Number: 2607 • 2013 ACR/ARHP Annual Meeting
Evaluation Of The Construct Validity Of The Patient-Reported Outcomes Measurement Information System (PROMIS®) Gastrointestinal (GI) Symptoms Measures In Systemic Sclerosis (SSc)
Dinesh Khanna¹, Puja Khanna¹, Brennan Spiegel², Lin Chang³, Gil Y. Melmed⁴, Roger Bolus⁵ and Ron Hays⁶, ¹Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²Gastroenterology; Health Policy and Management, Cedars-Sinai Health System and UCLA School of Medicine and Public Health, Los Angeles, CA, ³Medicine, Division of Digestive Diseases, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, ⁴Inflammatory Bowel Disease Center, Cedar-Sinai Medical Center, Los Angeles, CA, ⁵Research Solutions Group, Encinitas, CA, ⁶Medicine, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: As part of the National Institutes of Health PROMIS¨ roadmap initiative, we developed GI Symptoms measures that assess 8 domains: Gastroesophageal reflux (13 items),…
Abstract Number: 2530 • 2013 ACR/ARHP Annual Meeting
Sustained Improvements In Health-Related Quality Of Life In Patients With Systemic Lupus Erythematosus following Epratuzumab Treament: Results from a Phase IIb Trial and Its Open-Label Extension
Vibeke Strand¹, Joan T. Merrill², Enkeleida Nikaï³, Brian Kilgallen⁴, Antoine Regnault⁵ and Caroline Gordon⁶, ¹Stanford University, Palo Alto, CA, ²Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³UCB Pharma, Brussels, Belgium, ⁴UCB Pharma, Raleigh, NC, ⁵Mapi HEOR & Strategic Market Access, Lyon, France, ⁶Rheumatology Research Group (East Wing), School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Epratuzumab is a monoclonal antibody targeting CD22. Improvements in health-related quality of life (HRQoL) with epratuzumab in patients with systemic lupus erythematosus (SLE) have…
Abstract Number: 2504 • 2013 ACR/ARHP Annual Meeting
Male Children With Higher SLE Disease Activity In An US Cohort
Lakshmi N. Moorthy¹, Elizabeth Roy², Margaret Peterson³, Afton L. Hassett⁴, Alexa B. Adams⁵, Laura V. Barinstein⁶, Elizabeth C. Chalom⁷, Karen Onel⁸, Linda Ray⁹, Jorge Lopez-Benitez¹⁰, Kathleen A. Haines¹¹, Philip Hashkes¹², Daniel J. Kingsbury¹³, Victoria Cartwright¹⁴, Nora G. Singer¹⁵, Ingrid Tomanova-Soltys¹⁶, Andreas Reiff¹⁷, Sandy D. Hong¹⁸ and Thomas J. A. Lehman¹⁹, ¹Pediatric Rheumatology, Robert Wood Johnson Medical School-Rutgers University, New Brunswick, NJ, ²RWJMS-UMDNJ, New Brunswick, NJ, ³Hospital for Special Surgery, New York, NY, ⁴Anesthesiology, University of Michigan, Ann Arbor, MI, ⁵Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Pediatric Rheumatology, Mount Sinai Med Ctr, New York, NY, ⁷Pediatrics, St. Barnabas Medical Center, Livingston, NJ, ⁸Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, ⁹Pediatric Rheumatology, University of Mississippi Medical Center, Jackson, MS, ¹⁰Pediatric Rheumatology Program Centro Medico La Costa, Asuncion, Paraguay, ¹¹Department of Pediatrics, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ¹²Pediatric Rheumatology, Shaare Zedek Medical Center, Jerusalem, Israel, ¹³Randall Children's Hospital at Legacy Emanuel, Portland, OR, ¹⁴Legacy Emanuel Children's Hospital, Portland, OR, ¹⁵Medicine, Division of Rheumatology, MetroHealth Medical Center, Cleveland, OH, ¹⁶Winthrop University Hospital, Mineola, NY, ¹⁷Division of Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, ¹⁸Pediatrics-Rheumatology, U of Iowa Children's Hosp, Iowa City, IA, ¹⁹Chief Div Ped Rheum PTD, Hospital for Special Surgery, New York, NY
Background/Purpose: Although systemic lupus erythematosus (SLE) is more common in females, males tend to have more severe disease. We compared age at SLE diagnosis, duration,…
Abstract Number: 1996 • 2013 ACR/ARHP Annual Meeting
Racial/Ethnicity Differences In Health-Related Quality Of Life (HRQOL), Functional Ability and Health Care Utilization In Gout Patients
Aseem Bharat¹, Jasvinder A. Singh^2,3, Puja Khanna⁴, Cleopatra Aquino-Beaton⁵, Jay E. Persselin⁶, Erin Duffy⁷, David Elashoff⁸ and Dinesh Khanna⁹, ¹Medicine/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology, Birmingham VA, Birmingham, AL, ³Department of Medicine, University of Alabama, Tuscaloosa, AL, ⁴Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁵Rheumatology, VA Greater Los Angeles Healthcare System, Los Angeles, CA, ⁶Medicine W-111J Div of Rheum, VA Greater Los Angeles Healthcare System, Los Angeles, CA, ⁷Medicine, University of California Los Angeles, Los Angeles, CA, ⁸Medicine- Statistic Core, UCLA Department of Medicine Statistics Core, Los Angeles, CA, ⁹University of Michigan, Ann Arbor, MI
Background/Purpose: Due to limited/no data for race/ethnicity, our objective was to assess whether HRQOL functional ability and health care utilization in gout patients differs by…
Abstract Number: 1520 • 2013 ACR/ARHP Annual Meeting
Reduction Of Disease Burden On Workplace and Household Productivity In Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis, Over 48 Weeks Of Treatment With Certolizumab Pegol
Désirée M. van der Heijde¹, Jürgen Braun², Martin Rudwaleit³, Oana Purcaru⁴ and Arthur Kavanaugh⁵, ¹Dept of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³Endokrinologikum, Berlin, Germany, ⁴UCB Pharma, Brussels, Belgium, ⁵Division of Rheumatology Allergy and Immunology, University of California San Diego, San Diego, CA
Background/Purpose: Axial spondyloarthritis (axSpA) includes both ankylosing spondylitis (AS, meeting modified New York criteria) and axSpA with no sacroiliitis on X-ray (non-radiographic axSpA, nr-axSpA). AS…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].